The binding of therapeutic antibodies to CD64 is of particular interest, as CD64+ myeloid cells producing IL-23 are increased in the inflamed colon in IBD, and this binding might potentially enhance IL-23 blockade. Here, FCGR1A is linked to inflammatory bowel disease.